Clinical Research Directory
Browse clinical research sites, groups, and studies.
177Lu-AB-3PRGD2 in Patients With Integrin αVβ3 Positive Tumors
Sponsor: Peking Union Medical College Hospital
Summary
This is an open-label, non-controlled, non-randomized study to assess the safety and measure image-based absorbed dose of 177Lu-AB-3PRGD2 in patients with Integrin αVβ3 positive tumors who will undergo radioliagnd therapy using 177Lu-AB-3PRGD2.
Official title: Therapeutic Efficiency and Response to 177Lu-AB-3PRGD2 in Patients With Integrin αVβ3 Positive Tumors
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2021-10-01
Completion Date
2024-12-01
Last Updated
2024-06-13
Healthy Volunteers
No
Conditions
Interventions
1.48 GBq of 177Lu-AB-3PRGD2
accepted intravenous injection of 177Lu-AB-3PRGD2
Locations (1)
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China